A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults

被引：55

作者：

Karron, Ruth A. ^{[1
]}

Callahan, Karen ^{[1
]}

Luke, Catherine ^{[2
]}

Thumar, Bhagvanji ^{[1
]}

McAuliffe, Josephine ^{[2
]}

Schappell, Elizabeth ^{[1
]}

Joseph, Tomy ^{[2
]}

Coelingh, Kathleen ^{[3
]}

Jin, Hong ^{[3
]}

Kemble, George ^{[3
]}

Murphy, Brian R. ^{[2
]}

Subbarao, Kanta ^{[2
]}

机构：

[1] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA

[2] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA

[3] MedImmune, Gaithersburg, MD USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2009年 / 199卷 / 05期

基金：

美国国家卫生研究院;

关键词：

CANDIDATE VACCINES; PANDEMIC INFLUENZA; DOSE-RESPONSE; H5N1; VIRUS; VOLUNTEERS; REASSORTANT; INFECTION; ANTIBODY; SAFETY;

D O I：

10.1086/596558

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intra-nasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had >= 4-fold increases in hemagglutination-inhibition antibody, and 79% had >= 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults. Trial registration. ClinicalTrials.gov identifier: NCT00110279.

引用

页码：711 / 716

页数：6

共 15 条

[11] Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines [J].

Murphy, BR ;

Coelingh, K .

VIRAL IMMUNOLOGY, 2002, 15 (02) :295-323

[12] Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays [J].

Rowe, T ;

Abernathy, RA ;

Hu-Primmer, J ;

Thompson, WW ;

Lu, XH ;

Lim, W ;

Fukuda, K ;

Cox, NJ ;

Katz, JM .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (04) :937-943

[13] Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults:: phase I randomised trial [J].

Stephenson, I ;

Nicholson, KG ;

Glück, R ;

Mischler, R ;

Newman, RW ;

Palache, AM ;

Verlander, NQ ;

Warburton, F ;

Wood, JM ;

Zambon, MC .

LANCET, 2003, 362 (9400) :1959-1966

[14] Development of effective vaccines against pandemic influenza [J].

Subbarao, K ;

Murphy, BR ;

Fauci, AS .

IMMUNITY, 2006, 24 (01) :5-9

[15] Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets [J].

Suguitan, Amorsolo L., Jr. ;

McAuliffe, Josephine ;

Mills, Kimberly L. ;

Jin, Hong ;

Duke, Greg ;

Lu, Bin ;

Luke, Catherine J. ;

Murphy, Brian ;

Swayne, David E. ;

Kemble, George ;

Subbarao, Kanta .

PLOS MEDICINE, 2006, 3 (09) :1541-1555

← 1 2 →